Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Agennix Clear all
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
Satraplatin, Prednisone
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
105
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1 Interventional

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01528137
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 2 Interventional

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00268970
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Satraplatin in combination with Paclitaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1 Interventional

Study of Satraplatin (JM-216) in Combination With Docetaxel

NCT00125411
View directory record Official record
Conditions
Tumors
Interventions
satraplatin and docetaxel
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 2 Interventional

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

NCT00095186
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Recombinant Human Lactoferrin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1 Interventional

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

NCT00329329
View directory record Official record
Conditions
Malignancies
Interventions
satraplatin and capecitabine
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 2 Interventional

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

NCT00265655
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 2 Interventional

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1 Interventional

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

NCT00480623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Satraplatin plus radiation therapy
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
San Francisco, California • Dallas, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Not listed Phase 1Phase 2 Interventional

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

NCT00854633
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
1 Minute to 24 Hours
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 1 Interventional

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720
View directory record Official record
Conditions
Advanced Cancers
Interventions
Satraplatin, Abraxane
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1 Interventional

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

NCT00313456
View directory record Official record
Conditions
Tumors, Prostate Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Not listed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

NCT00706862
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 3 Interventional

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

NCT00450970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Oral Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
121
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

NCT00630656
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Loma Linda, California • Sacramento, California • Sylmar, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Nov 15, 2026, 4:53 AM EST
Terminated Phase 1Phase 2 Interventional

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

NCT00093132
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung, Lung Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Completed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Nov 15, 2026, 4:53 AM EST
Suspended Phase 2Phase 3 Interventional

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 15, 2026, 4:53 AM EST